Tackling EGFR signaling with TACE antagonists: A rational target for metalloprotease inhibitors in cancer

Paraic A. Kenny

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.

Original languageEnglish (US)
Pages (from-to)1287-1298
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume11
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Metalloproteases
Epidermal Growth Factor Receptor
Tumors
Arthritis
Neoplasms
Ligands
Membranes
Enzymes
ADAM17 Protein

Keywords

  • ADAM17
  • Cancer
  • EGFR
  • Metalloprotease inhibitor
  • Sheddase

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tackling EGFR signaling with TACE antagonists : A rational target for metalloprotease inhibitors in cancer. / Kenny, Paraic A.

In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 10, 10.2007, p. 1287-1298.

Research output: Contribution to journalArticle

@article{139f00de7ce844af9503c91a8f998e4e,
title = "Tackling EGFR signaling with TACE antagonists: A rational target for metalloprotease inhibitors in cancer",
abstract = "TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.",
keywords = "ADAM17, Cancer, EGFR, Metalloprotease inhibitor, Sheddase",
author = "Kenny, {Paraic A.}",
year = "2007",
month = "10",
doi = "10.1517/14728222.11.10.1287",
language = "English (US)",
volume = "11",
pages = "1287--1298",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Tackling EGFR signaling with TACE antagonists

T2 - A rational target for metalloprotease inhibitors in cancer

AU - Kenny, Paraic A.

PY - 2007/10

Y1 - 2007/10

N2 - TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.

AB - TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.

KW - ADAM17

KW - Cancer

KW - EGFR

KW - Metalloprotease inhibitor

KW - Sheddase

UR - http://www.scopus.com/inward/record.url?scp=35348962179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348962179&partnerID=8YFLogxK

U2 - 10.1517/14728222.11.10.1287

DO - 10.1517/14728222.11.10.1287

M3 - Article

C2 - 17907959

AN - SCOPUS:35348962179

VL - 11

SP - 1287

EP - 1298

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 10

ER -